The complexity, function, and applications of RNA in circulation

Alton Etheridge1, Clarissa R C. Gomez2,3, Rinaldo W. Pereira3, David Galas1,4 and Kai Wang2

1 Pacific Northwest Diabetes Research Institute, Seattle, WA, USA
2 Institute for Systems Biology, Seattle, WA, USA
3 Graduation on Genomic Sciences and Biotechnology, Catholic University of Brasilia, Brasilia, Brazil
4 Luxembourg Centre for Systems Biomedicine, University of Luxembourg, Luxembourg, Luxembourg

*Correspondence: kai.wang@pnri.org

Blood carries a wide array of biomolecules, including nutrients, hormones, and molecules that are secreted by cells for specific biological functions. The recent finding of stable RNA of both endogenous and exogenous origin in circulation raises a number of questions and opens a broad, new field: exploring the origins, functions, and applications of these extracellular RNA molecules. These findings raise many important questions, including: what are the mechanisms of export and cellular uptake, what is the nature and source of their stability, what molecules do they interact with in the blood, and what are the possible biological functions of the circulating RNA? This review summarizes some key recent developments in circulating RNA research and discusses some of the open questions in the field.

Keywords: microRNA, exosomes, microvesicles, cell–cell communication, exogenous RNA

Coordination of the activities of different cells in the body is vital for multi-cellular organisms. For this purpose, at least three different types of intercellular communication systems have evolved. Physical interactions between cells through cell surface protein engagement like that between receptors and ligands are used to transmit signals between close, contacting cells (Schoenbeck and Libby, 2001; Chilakuri et al., 2012). Gap junctions can also facilitate the transmission of molecular signals between cells (Vallinas et al., 2005; Wolfstang et al., 2007; Lim et al., 2011). Membrane nanotubes or cytonemes that extend up to 100 μm in length are physical connections that also allow communication between cells that are not immediately adjacent to each other (Gerdès and Carvalho, 2008). Multi-cellular organisms have also developed a network of circulating body fluids to deliver nutrients to cells, remove waste molecules, and transmit signals for “long-distance” cell–cell and organ–organ communication. The combination of the circulation system with central and peripheral neural networks, and other short and medium range communication processes, allows cells and organs in an organism to operate in close concert. Some circulating proteins or peptides are well-known for their roles as signaling molecules. These include hormones such as insulin, growth hormone, prolactin, and many other secreted proteins/peptides. In addition to these well-known examples, other biomolecules such as nucleic acids are also exported from cells and are present in various body fluids (Valadi et al., 2007; Weber et al., 2010), although their potential roles in intercellular and other short and medium range communication processes, allows cells and organs in an organism to operate in close concert. Some circulating proteins or peptides are well-known for their roles as signaling molecules. These include hormones such as insulin, growth hormone, prolactin, and many other secreted proteins/peptides. In addition to these well-known examples, other biomolecules such as nucleic acids are also exported from cells and are present in various body fluids (Valadi et al., 2007; Weber et al., 2010), although their potential roles in intercellular signaling have not been confirmed. While the discovery of circulating extracellular nucleic acid is not new, having been described as early as 1948 (Mandel and Métais, 1948), there has been a renewed interest in the function and application of circulating nucleic acids due to several, diverse recent findings. These include the discoveries of fetal DNA in maternal blood (Lo and Chiu, 2012), tumor-derived DNA in circulation (Kohler et al., 2011) and stable regulatory non-coding RNA (ncRNA) in body fluids (Cortez et al., 2011).

RNA is generally considered to be an unstable molecule that is subject to degradation and turnover by ubiquitous RNAse activity. However, intact RNAs of different types, including both protein-coding RNA (mRNA) and non-coding RNA (ncRNA) have been detected in circulation (Valadi et al., 2007). Some of these RNAs are likely the result of cell lysis through normal cell turnover and are in the process of degradation, reabsorption, or excretion (Turchinovich et al., 2011). However, the abundance and high stability of some of these RNA molecules, especially the short regulatory RNA, microRNA (miRNA), suggests a different scenario: the possibility of a cell–cell communication system through RNA-mediated signals (Lottavall and Valadi, 2007; Turchinovich et al., 2011; Montecelbo et al., 2012). Furthermore, recent studies have shown that exogenous RNA molecules can enter into circulation through the diet or other means, and can potentially be taken up by cells and thereby alter the cellular transcriptome (Semenov et al., 2012; Wang et al., 2012; Zhang et al., 2012a). Many questions remain unanswered, however, including: what are the sources of endogenous and exogenous RNA molecules in circulation, what is (are) the mechanism(s) by which these RNAs enter into circulation, how are they stabilized there, are they taken up by cells, and how are...
they recognized for uptake by cells? Here we review several recent developments in the study of circulating RNAs and their potential functions and possible applications.

**EXTRACELLULAR RNA IN BODY FLUIDS**

Among all the circulating nucleic acids, miRNAs are probably the most extensively studied. These small molecules are short, nRNAs involved in regulating the cellular transcriptome and proteome by destabilizing mRNA and/or attenuating protein translation (Filipowicz et al., 2008; Fabian et al., 2010). The interaction between miRNAs and their cognate mRNA targets is mediated by partial sequence complementarity between the two (Fabian et al., 2010). The RNA-induced silencing complex (RISC), which contains a number of proteins including members of the Argonaute family, the RNA recognition motif containing protein TNRC6B, putative DNA helicase MOV10, among others, is involved in the miRNA–mRNA interaction (Chendrimada et al., 2007).

MicroRNAs were first detected in the blood plasma and serum in 2008 (Chen et al., 2008; Chim et al., 2008; Hunter et al., 2008; Lawrie et al., 2008; Mitchell et al., 2008; Skog et al., 2008) and have subsequently been detected in many other different body fluids including urine, saliva, tears, and breast milk (Park et al., 2009; Hanke et al., 2010; Weber et al., 2010). The total amount and the concentration of individual miRNAs vary widely among the different fluid types (Weber et al., 2010). The potential of circulating miRNAs as biomarkers has been extensively investigated in recent years. miRNAs make good biomarker candidates for several reasons. They are stable in body fluids, which are easy to obtain from patients, they can be easily measured with high sensitivity because they are amplifiable, and some markers and sets of markers have shown profiles associated with specific pathologies. The changes in miRNA levels may be used as a diagnostic tool for several types of cancer (Mitchell et al., 2008; Taylor and Gerec-Taylor, 2008; Park et al., 2009; Hanke et al., 2010; Huang et al., 2010; Zhao et al., 2010; Mousay et al., 2011; Roth et al., 2011), cardiac damage (Ai et al., 2010; Costen et al., 2010; Tijssen et al., 2010; Wang et al., 2010a), muscular injury and pathologies (Latezza et al., 2009; Mizuno et al., 2011; Vignier et al., 2013), diabetes (Chen et al., 2008; Erner et al., 2013), liver injury (Latezza et al., 2009; Wang et al., 2009, 2013; Starkey Lewis et al., 2011), among others.

The literature reporting correlations with human disease and pathologies has grown rapidly in the past few years. The number of papers, for example, on changes in circulating miRNAs in cases of myocardial infarction (MI) and cardiac diseases alone has recently exploded. We estimate that more than 30 reports on this specific topic alone have been published since 2009. Some of the circulating miRNAs identified in MI and cardiac diseases have been summarized in Table 1.

Efforts have also been made to use circulating miRNAs as a prognostic tool in response to therapeutic treatments (Ma et al., 2012). Furthermore, the possibility of using miRNAs as therapeutics themselves has been considered. It is a very exciting prospect if these molecules can be packaged and released into circulation as stable and perhaps even targeted packages. Applications in this area have taken different approaches. For example, creating synthetic miRNAs designed to target specific disease-associated genes, as used by Suckau et al. (2009) to treat heart failure. In this case, viral vectors containing short hairpin RNAs were administered intravenously in rats to reduce the level of a key regulator of cardiac calcium homeostasis, phospholamban (Suckau et al., 2009).

The use of antagonors to target miRNAs that are upregulated in pathologic states has also been demonstrated. For example, an antagonist of miR-133 caused sustained cardiac hypertrophy in mice (Care et al., 2007); antagonors targeting miR-1 and let-7 were successfully used in rats to extend neuroprotection after ischemic stroke (Selvamani et al., 2012); mice treated with high doses of an antagonist for miR-126 showed reduced ischemia-induced angiogenesis (van Solingen et al., 2009); and a miR-206 antagonist increased brain-derived neurotrophic factor levels and improved memory function in rats with Alzheimer’s disease (Lee et al., 2012). Furthermore, a treatment for hepatitis C Virus (HCV) chronic infection using an antagonist for the liver-specific miR-122 is currently in clinical trial (Jansen et al., 2013).

**RNA EXPORT, PACKAGING, AND UPTAKE**

While extracellular RNAs were first thought to be molecular debris released by cell lysis (Turchinovich et al., 2011), the difference in the spectrum of RNA within cultured cells and the external medium argues strongly for selective export of some fraction of the circulating RNAs (Wang et al., 2010b). It remains unclear how specific RNAs are targeted for export, and if some are simply released with the cytosol through bulk exocytosis. As free RNA molecules are very likely to be degraded outside the cell, it is generally assumed that circulating RNAs are packaged in some form to avoid RNase degradation. Lipid vesicles, such as exosomes or microvesicles are one type of packaging system used by secreted RNAs (Valadi et al., 2007; Camussi et al., 2011). Exosomes, which are approximately 30–100 nm in diameter, are formed by fission of multivesicular bodies with the plasma membrane. Microvesicles are larger (100 nm–1 μm) and formed by blebbing of the plasma membrane. Both types of vesicles can contain a number of protein and RNA molecules, although the composition varies widely with the origin of the vesicle (Muller, 2012; Huang et al., 2013).

In addition to lipid vesicles, it has been demonstrated that miRNA in the extracellular environment can complex with high-density lipoproteins (HDL) and at least two RNA-binding proteins in vivo. Argonaute 1 (AGO1) and Argonaute 2 (AGO2), and with nucleophosmin 1 (NPM1) in vitro (Wang et al., 2010b; Arroyo et al., 2011; Turchinovich et al., 2011; Vickers et al., 2011; Turchinovich and Burwinkel, 2012; Wagner et al., 2013). Furthermore, the spectrum of miRNA associated with HDL depends on the health status of an individual (Vickers et al., 2011). However, it is not known if there are other RNA-binding proteins that form similar complexes to protect miRNAs or other types of RNA in circulation.

Besides miRNAs, lipid vesicles also contain a large number of protein-coding RNAs. Roughly 1500 different mRNA transcripts have been identified in lipid vesicles derived from human or mouse cell lines (Valadi et al., 2007). Interestingly, the mRNA composition and abundance in the exosomes differ from that of the original cell, which suggests the contents in the lipid vesicles are selectively packaged rather than included indiscriminately. The levels...
Table 1 | Circulating miRNAs with biomarker potential to diagnose acute myocardial infarction (AMI).

| Candidate miRNA(s) | Organism | Source | Sample size | Correlation | Reference |
|--------------------|----------|--------|-------------|-------------|-----------|
| 1, 133a, 133b, 499-5p | Human; mouse | Plasma | 33 patients, 17 healthy; 4–5 AMI and control mice | Elevated levels distinguished cardiac damage patients from healthy subjects. Positive correlation with TnIa | D’Alessandra et al. (2010) |
| 1 | Human; rat | Serum | 31 patients, 20 healthy; 8 AMI rats, 8 controls | High expression was associated with CK-MBb; positive correlation with myocardial infarct size | Cheng et al. (2010) |
| 1 | Human | Plasma | 33 patients, 30 healthy | Up-regulation correlated with QRS duration | Ai et al. (2010) |
| 208a | Human | Plasma | 93 patients, 66 healthy | Present only in patients and showed to be more specific and sensitive than TnIa | Wang et al. (2010a) |
| 208b, 499 | Human | Plasma | 32 patients, 36 healthy | High levels correlated with TnTd and CPKe | Devaux et al. (2012) |
| 499 | Human | Plasma | 9 patients, 10 healthy | Elevated expression correlated positively with CK-MB activity | Adachi et al. (2010) |
| 1, 133a | Human | Serum | 29 patients, 42 non-AMI | Increased levels showed correlation with TnTd | Kuwabara et al. (2011) |
| 133, 328 | Human | Plasma, whole blood | 51 patients, 28 healthy | High levels correlated with TnTd | Wang et al. (2011) |
| 30c, 145, 1291, 663b | Human | Whole blood | 20 patients, 20 non-AMI | Elevated levels of 30c and 145 correlated with TnTd; 1291 and 663b distinguished patients from healthy subjects | Medor et al. (2011) |
| 208b, 499 | Human | Plasma | 510 patients, 87 healthy | Increased levels correlated with peak concentrations of CPKe and TnTd | Devaux et al. (2012) |

*aCardiac troponin I; bcreatine kinase muscle b; cQRS complex in an electrocardiogram; dcardiac troponin T; ecreatine phosphokinase.
of circulating miRNAs as well as several mRNAs in circulation have been shown to be associated with stages and types of cancers (Sasaki et al., 2005; Mitchell et al., 2002; Taylor and Gercel-Taylor, 2008; Oshimia et al., 2010; Zhao et al., 2012; Zhang et al., 2012b), pregnancy (Zhong et al., 2008; Rajakumar et al., 2012; Wu et al., 2012; Zhao et al., 2012; Higashijima et al., 2013), and drug-induced liver injury (Miyamoto et al., 2008; Laterza et al., 2009; Wang et al., 2009, 2013; Bala et al., 2012; Su et al., 2012; Okubo et al., 2013).

The idea of using RNA as a mode of intercellular communication is particularly interesting for several reasons. First, RNA can carry information in a simple and efficient way (such as coding for proteins in mRNA), and, second, it can coordinate cellular activity in a fundamental and essential manner (such as miRNA-mediated transcriptional regulation and proteome regulation). It has been demonstrated that cells can export miRNAs, which can be transferred to and are functional in recipient cells (Bonsaka et al., 2010; Zhang et al., 2010; Hergens thrilled et al., 2012). However, it is inherently difficult to test definitively the functionality of an RNA-based communication system in vivo. Conditioned media exchange and co-culture experiments have been used to investigate cell-cell communications, and these methods have been adapted to investigate the possibility of RNA uptake by cells (Liu et al., 2010; Vencio et al., 2011; Xing et al., 2011). Some exosome-derived miRNAs have been shown to be functional in recipient cells (Valadi et al., 2007; Ismail et al., 2013). Furthermore, Ratajczak et al. (2006) showed that microvesicles derived from embryonic stem cells can enhance the survival and expansion of mouse hematopoietic progenitor cells, and are enriched in stem cell related transcripts including Oct-4, Rex-1, Nanog, SCL, and GATA-2. Reporter assays have shown that exosome-derived miRNAs can silence transcripts in recipient cells (Lotvall and Valadi, 2007; Valadi et al., 2007; Camussi et al., 2011; Kogure et al., 2011; Mittelbrunn et al., 2011). While evidence suggests that cultured cells can transfer packaged RNA molecules, it is difficult to demonstrate this as a general mechanism in vivo. One of the most important remaining biochemical questions is how the RNA in circulation is protected, packaged, and delivered to and recognized by their targets. The current lack of knowledge about these questions makes the study of the biological functions of circulating RNA both important and difficult.

Besides protein-coding RNAs and miRNAs, there are other more abundant types of regulatory RNA molecules, such as large intergenic non-coding RNAs (lincRNAs) and small nuclear RNAs (snRNAs) in extracellular vesicles (Huang et al., 2013). A recent characterization of neuronal exosomes found RNAs derived from repeat sequences, as well as miRNA and several types of small RNAs. While a majority of small RNA was RNA (90%), other types of small RNAs including miRNA, snoRNA, and small cytoplasmic RNA (scRNA) were also detected (Bellingham et al., 2012). Since both miRNA and mRNA can be taken up and utilized by cells (see earlier paragraphs), there is no reason to think that other types of RNA in circulation do not also have functional implications when they are taken up by cells. However, there is currently no direct experimental evidence to support this functional possibility for other types of RNA in circulation.

**METHODS USED IN STUDYING RNA IN CIRCULATION**

Microarray, qPCR (quantitative polymerase chain reaction), and sequencing-based approaches are the three major platforms that have been used for miRNA and mRNA profiling. All of these have been widely and successfully applied in assessing the spectra of mRNA and miRNA in cells and tissues. However, due to the relatively low concentration of RNA present in circulation, comprehensive measurement of any circulating RNA is difficult to do accurately and consistently. For miRNAs, the difficulties are compounded by the short lengths of the RNA molecules and the consequent sequence specificity of hybridization free energies. At the moment, the most commonly used method for miRNA profiles is qPCR because of its sensitivity and the limited number of known miRNAs (on the order of 1800 sequences). This method has significant drawbacks as well because of the specificity and differential amplification efficiency of the designed primers. This technique has also been applied to measure the level of specific mRNA sequences in circulation (Wang et al., 2013). Although microarrays have been the gold standard for transcriptome analysis in cells and tissues, the low concentration of RNA in circulation, and the sequence similarity of these short nucleic acid molecules make microarray analysis unsuitable in most cases. The development of next generation sequencing (NGS) has shown promise in measuring circulating RNAs. This platform not only solves some of the miRNA measurement problems related to short and highly similar sequences of miRNAs, but it can provide measurements on a broad spectrum of RNA in a single experiment. Because it does not rely on pre-designed probes or primers, NGS also allows the identification of novel RNA sequences, such as isomirs and exogenous RNAs in circulation (Lee et al., 2010; Wang et al., 2010a, 2012; Semenov et al., 2012). One difficulty with this method is the inherent bias in the preparation of the sequencing libraries. For this reason, absolute measurements of circulating RNA are very difficult, but when carefully done, comparative measurements can be reliable.

**EXOGENOUS RNA IN CIRCULATION**

Recent evidence, which we discuss below, suggests that RNAs in circulation are derived not only from cells within the human body, but also from foreign organisms and viruses (Meckes et al., 2010; Pegel et al., 2010). It has been shown that exogenous RNAs find their way from the outside environment, through diet or from the complex human microbiome (Zhang et al., 2012a). Little is known about how exogenous RNAs are taken up by the gut epithelium from the environment, and there is only very limited and circumstantial evidence so far that these RNAs are functional in the body. However, in keeping with the substantial and growing body of evidence that some human circulating RNA are functional, the possibility that exogenous RNAs, found in the circulation can be taken up and exert specific functions in recipient cells, raises several interesting issues. A recent report by Zhang et al. (2012a) indicated that exogenous miRNAs ingested from food (rice in this case) could enter into the human circulation and be taken up by and actually function in cells. They found that certain plant miRNAs, including miR 166a, an abundant miRNA in rice, is detectable in human plasma, as well as in plasma from other animals eating a diet containing plant.
material. However, many questions such as how the RNA survives the cooking process and the harsh environment of the digestive tract, as well as how these biomolecules can pass through the gut epithelium, remain largely unanswered. Using Caco-2 cells transfected with synthetic rice miR-168a, Zhang et al. (2012a) found that transfected miR-168a can be packaged by cells into microvesicles and released into culture medium. Furthermore, their work suggests that the microvesicles containing exogenous miRNA can be taken up by cells and interact with endogenous transcripts both in vitro and in vivo. Mature miR-168a sequence has significant sequence homology with a liver-expressed transcript, low-density lipoprotein receptor adaptor protein 1 (LDLRAP1) transcript, raising the possibility that it can suppress the expression of LDLRAP1 through the action of the RISC complex. Indeed, mice fed a rice-containing diet have lower level of LDLRAP1 gene expression than mice fed a normal chow diet, suggesting that miR-168a derived from the rice can affect the level of an endogenous mouse transcript (Zhang et al., 2012a).

Recent work by our lab and others have systematically characterized the composition of RNAs in circulation and revealed that some of the circulating RNAs are derived from a variety of exogenous organisms, including the microbiome (Semenov et al., 2012; Wang et al., 2012, 2013). Using a map-and-remove strategy to analyze small RNA-seq data (after removing sequences mapped to human miRNAs, transcripts, and genomic sequences first), reveals that a significant portion of the total reads are of non-human origin. While some of these exogenous RNAs are derived from the diet, the majority of them are of either fungal or bacterial origin (Wang et al., 2012). The sequences detected implicate a wide range of bacterial phyla, including many already known to reside in the gut microbiome. Although there were not significant differences in the plasma RNA spectra between healthy individuals and those with colorectal cancer or ulcerative colitis, differences can be detected in the plasma of people eating different diets, such as a corn-based diet versus a rice-based diet (Wang et al., 2012).

While these results raise the interesting possibility that exogenous RNAs taken up from the environment can alter gene expression in the cells of an organism, many questions remain unanswered. How these RNAs pass through the body’s epithelial barrier and enter the circulation, for example, is still completely unclear. Because of the relatively low levels of exogenous circulating RNA, it seems likely that if the packages containing exogenous RNAs exert a significant biological effect on the body’s cells they must be effectively targeted in some way to specific cells or tissues.

Since some miRNAs are highly conserved in metazoans (Shi et al., 2012), the finding of diet derived exogenous RNA in circulation raises the interesting possibility that there are RNA-based processes that either induce or avert the development of diseases in humans arising from foreign RNA. For example, changing the levels of certain highly conserved miRNAs, such as miR-21, which has solid pro-proliferation activity (Saday et al., 2008; Yao et al., 2009), and miR-150 and miR-146, which have strong association with inflammation activities (Sheedy and O’Neill, 2008; Sunolky et al., 2008; Schmidt et al., 2009; Quin and O’Neill, 2011; Zhong et al., 2012), by uptake of exogenous RNAs with similar activities may affect the initiation and progression of certain diseases. Although promising both as biomarkers and potential functional impacts, such as for therapeutics, there is still a great deal to be learned about RNA in circulation. This newly recognized class of circulating molecules has the potential to be deeply involved in the symbiotic functioning of the human body and its microbiome. We currently know very little about the potential mechanisms of entry of RNAs into circulation, their mechanisms of action, their packaging and export process, and their targeting and uptake by cells. Technical improvements and standardization in measuring the levels of these RNAs as well as new model experimental systems are needed in order to explore the many facets of the transport, targeting, and function of these RNAs. In summary, the health impact of RNAs in circulation seems likely to be significant, but the field is just beginning to be explored and the investigation of the area of the quantitative characterization and specific biological functions of exogenous RNA is even earlier in its development.
Hanke, M., Hoefig, K., Merz, H., Gerdes, H. H., and Carvalho, R. N. Devaux, Y., Vausort, M., Goretti, A. K., and Calin, G. A. (2011). Circulating RNA plasma-derived exosomal RNAs by Etheridge et al. Characterization of human pregnancy. Nat. Rev. Genet. doi: 10.1038/ncb2441

Feller, A. C., Kausch, I., Jocham, O., Hechel, H., and Kiehl, T. J. (2013). Circulating miR-155 as a biomarker of beta-cell death and diabetes in mice. Endocrinology 154, 650–658. doi: 10.1210/en.2012-1794

Fabián, M. B., Senesen, N., and Filipowicz, W. (2010). Regulation of mRNA translation and stability by microRNAs. Annu. Rev. Biochem. 79, 351–379. doi: 10.1146/annurev.biochem-060809-134400

Huang, X., Yuan, T., Tsuchida, M., Sun, Z., Jacob, H., Hu, D., and Xi, M. (2013). Characterization of human plasma-derived exosomal RNAs by deep sequencing. BMC Genomics 14:319. doi: 10.1186/1471-2164-14-319

Huang, Z., Huang, D., Ni, S., Peng, Z., Wang, W., and Xu, X. (2010). Plasma microRNAs are promising novel biomarkers for early detection of colorectal cancer. J. Clin. Cancer 127, 118–126. doi: 10.1002/jca.22067

Jessen, H. L., Bonnin, H. W., Lasztz, E. J., Reznik, Z., Rodriguez-Torres, M., Patel, K., et al. (2015). Treatment of HIV infection by targeting microRNA-122. Engl. J. Med. 368, 1651–1659. doi: 10.1056/NEJMoa1505806

Kojima, T., Wang, Y., Lin, K., Kondo, K., Matsuzaki, K., and Todo, T. (2011). Intracellular RNA transfection: a mechanism of environmental modulation of hepatocellular carcinoma growth. J. Gastroenterol. Hepatol. 26, 1237–1248. doi: 10.1111/j.1440-1758.2010.06908.x

Koide, T., Lim, W. Y., Lee, I. B., Roscioni, C., and Patel, T. (2011). Intercellular transfer of microRNA: a mechanism of environmental modulation of hepatocellular carcinoma growth. J. Gastroenterol. Hepatol. 26, 1225–1248. doi: 10.1111/j.1440-1758.2010.06908.x

Kawamura, Y., Inagaki, H., Sotomura, Y., Aihara, T., Takei, S., and Tsukada, Y. (2011). Increased mir-1 and microRNA-135a levels in serum of patients with cardiovascular disease indicate myocardial damage. Clin. Cardiol. 34, 109–113. doi: 10.1002/clc.20716

Kim, J. H., Huh, J. Y., Yoon, S., Park, J., Lee, S. K., and Choi, Y. S. (2011). miR-206 regulates the endoplasmic reticulum under the stress of liver-specific mRNA translation and stability by microRNA.

Lee, S. H., Chai, J., Long, J. H., Ihle, T., and Yoon, J. (2011). miR-206 regulates the endoplasmic reticulum under the stress of liver-specific mRNA translation and stability by microRNA.

Lee, S. M., Valsangkar, S. B., Mittal, D., Gell, J., et al. (2010). Complexity of the microRNA repertoire revealed by next-generation sequencing. RNA. 16, 2170–2180. doi: 10.1261/rna.222510

Li, Y., Pan, L., Li, Weihong, J., and Vinicius, E. F. (2011). Exosomal-RNA in maternal plasma. Cancer Biomarker 7, 99–106. doi: 10.3233/CBM-2011-0174

Lim, P. K., Xu, S., Patel, S. A., Taborga, M., Davis, M. A., Gregory, L. A., et al. (2011). Gag protein-mediated import of microRNA from bone marrow stromal cells can elicit cell cycle quiescence in breast cancer cells. Cancer Res. 71, 150–160. doi: 10.1158/0008-5472.CAN-10-2772

Lin, H. Y., Pouvil, E. L., Vinicius, R. Z., and Vinicius, E. F. (2011). Exosomal-RNA in maternal plasma. Cancer Biomarker 7, 99–106. doi: 10.3233/CBM-2011-0174

Liu, X., Yu, C., and Zhong, X. Y. (2011). Cell-free microRNA plasma: a potential biomarker of cardiovascular disease. Circ. Res. 108, 464–464. doi: 10.1161/CIRCRESAHA.110.279973

Liu, X., Lim, S., Ma, Y., Zhang, P., Wang, F., Zhang, H., Yang, J., and Peng, J. (2012). miR-191 in a potential biomarker associated with prognosis and therapeutic outcome in colorectal cancer. Cancer. 61, 1447–1455. doi: 10.3109/jc.2011-31122

Mandal, P., and Mirza, P. (1948). Les acides nucleiques du plasma sanguin chez l’homme. C. R. Acad. Sci. Paris 142, 158–158. doi: 10.1186/1471-2164-142-158

Miralles, D., Lopes, J., Brito, S., El-Gardani, G., et al. (2010). Use of microRNAs as stable blood-based markers for cancer detection. Proc. Natl. Acad. Sci. U.S.A. 107, 10513–10518. doi: 10.1073/pnas.1007984107

Mitchell, P. S., Parkin, R. K., Kosh, E. M., Fritz, B. R., Wyman, S. K., Pogosova-Agadjanyan, E. L., et al. (2008). Circulating microRNAs as stable blood-based markers for cancer detection. Proc. Natl. Acad. Sci. U.S.A. 105, 10513–10518. doi: 10.1073/pnas.1007984107
Ratajczak, J., Miekus, K., Kucia, M., Sayed, D., Rane, S., Lypowy, J., He, Rajakumar, A., Cerdeira, A. S., Rana, www.frontiersin.org Schonbeck, U., and Libby, P. (2001). The Quinn, S. R., and O'Neill, L. A. Pegtel, D. M., Cosmopoulos, K., Etheridge et al. Circulating RNA Abemayor, E., et al. (2009). Sali-

zontal transfer of mRNA and protein zation. and clinical utility for oral transcrip-
tional delivery. horizontal transfer of mRNA and pro-

tein. evidence for hori-

Zhang, J., Reca, R., Dvorak, P., et al. miRNA conservation.

Semenov, D. V., Burdakin, D., Breen, E., Kuvshinov, A. M., Vaskov, G. V., Brygden, L. A., et al. 2012. Unbiased approach to pro-

cfile the variety of small non-coding RNA of human blood plasma with

massively parallel sequencing tech-

ique. Expert Opin. Biol. Ther. 12 Suppl 1:453–501. doi: 10.1517/ 14721397.2012.679053

hoody, F. J., and O'Neill, L. A. (2012) adding fuel to fire: micro-

RNAs as a new class of media-
tors of inflammation. Ann. Rheum. Dis. 67 Suppl 3: i38–i47. doi: 10.1136/annrheumdis.2011.200299

Shu, R., Gao, W., and Wang, J. (2012) Sequence fingerprints of microRNA conservation. PLoS One 7 e38236. doi: 10.1371/journal.pone. 0046290

Shop, J., Wunderling, T., van Rijn, S., Meijer, D. H., Ganslo, L., Sene-Etevo, M., et al. (2008). Glioblastoma microvesicle transport RNA and proteins that promote tumour growth and provide diagnos-

tic biomarkers. Nat. Cell Biol. 10, 1470–1476. doi: 10.1038/nclm.2008.242

Jenkel, E., Stable, M., and Ponsioen, A. (2008). MicroRNAs and immunity: novel players in the regulation of nor-
mal immune function and inflamma-
tion. Semin. Cancer Biol. 18, 131–146. doi: 10.1016/j.semcancer.2008.01.005

Starkov, Louis P., J. Dose, J., Platt, Robert P., Tsai, Shu-Ching, L., Gupta, Harjot, C., Harbott, C., Chuang, P. R., Hoef, P., Sela, E., Eisele, H., et al. (2011). Circu-

lar microRNAs as potential marks-

ers of human drug-induced liver injury. Hypertension 57, 1673–1677. doi: 10.1161/HYP.0b013e3182254838

Su, Y. W., Chen, X., Zhang, J., Wang, T., Wang, C., Zhang, Y., et al. (2012). A panel of serum microRNAs as specific biomarkers for diagnosis of compounds- and barbituric acid-induced liver injury in rats. PLoS ONE 7 e37705. doi: 10.1371/journal.pone.0037705

Sucko, I., Fechner, H., Chemaly, E., Koshy, S., Halá, I., Kociskampfer, J., et al. (2009). Long-term cardiac-specific RNA interference for the treatment of heart failure restores cardiac function and reduces patho-

logic hypertrophy. Circ. Res. 105, 1241–1252. doi: 10.1161/CIRCULA-

tionaha.108.870852

Suokko, E., Suokko, N., Juutangu, K., Sato, A., Suga, K., Hayashi, S., et al. (2005). Detection of plasma hKlNP B1 mRNA, a new cancer biomarker in lung cancer patients by quantita-

tive real-time polymerase chain reac-

tion. Lung Cancer 48, 77–83. doi: 10.1016/j.lungcan.2004.10.007

Tayler, D. D., and Gerard-Taylor, C. (2009). MicroRNA signatures of tumor-derived exosomes as diagno-

tic biomarkers of ovarian cancer. Gynecol Oncol 115, 15–21. doi: 10.1016/j.ygyno.2008.04.053

Tian, A. J., Courtois, E. F., Moor-

land, P. D., de Winth, L. J., van der Wal, A. C., Kok, W. E., et al. (2010). MiR-425-3p as a circulating biomarker for a heart failure biomarker. Circ. Heart Fail. 10, 1055–1059. doi: 10.1177/1938227110371339

Turchinovich, A., and Baruscheck, B. (2011). Distinct AGO1 and AGO2 associated miRNA profiles in human cells and blood plasma. RNA 17, 1006–1017. doi: 10.1261/rna.218457

Turchinovich, A., Weiz, L., Langheinz, A., and Baruscheck, B. (2011). Characterization of extracellular circulating microRNA. Nucleic Acids Res. 39, 7225–7235. doi: 10.1093/nar/gkr2249

Valek, H., Ektorn, K., Rosova, A., Sperandio, M., Lee, J. H., and Leti-

va, J. O. (2007). Exosome-mediated transfer of miRNAs and microRNAs is a novel mechanism of genetic information exchange between cells. J. Cell Biol. 178, 654–670. doi: 10.1083/ nib.20076

Valianas, V., Polovina, Y. Y., Millet, H., Pologova, I. A., Vakanou, E., Dovrossimis, S., et al. (2005). Comissural-specific cell-to-cell trans-
fer of short interfering RNA by gap junctions. J. Physiol. 568, 459–468. doi: 10.1113/physiol.2005.080885

Solomon, C., Inghirami, L., Rub-

ner, R., Daise, J. M., Roeten, M., et al. (2003). Detection of plasma hKlNP B1 mRNA, a new cancer biomarker in lung cancer patients by quantita-

tive real-time polymerase chain reac-

tion. Lung Cancer 431, 2008.132.423–145. doi: 10.1161/clinchem.2010.147405

Wagner, J., Rosenlof, M., Besler, C., Sueoka, E., Sueoka, N., Iwanaga, K., Sueoka, E., Kuebler, W. C., Lill, S., et al. (2003). Novel potential biomarkers for drug-

induced liver injury. Proc. Natl. Acad. Sci. U.S.A. 100, 4602–4607. doi: 10.1073/pnas.0307771100

Wang, R., Li, H., Yuan, X., Elshageer, A., Zhou, Y., Huang, D., et al. (2012). The complex mammalian RNA spectra in human plasma: an inter-

face with human gut flora? PLoS ONE 7:e32662. doi: 10.1371/journal.pone.0032662

Wang, K., Zhang, S., Weber, J., Baxter, D., and Galus, D. J. (2008). Export of microRNAs and microRNA-

protective protein by mammalian cells. Nucleic Acids Res. 36, 7246– 7259. doi: 10.1093/nar/gkn348

Wang, K., Li, H., Yuan, X., Elshageer, A., Zhou, Y., Huang, D., et al. (2012). The complex mammalian RNA spectra in human plasma: an inter-

face with human gut flora? PLoS ONE 7:e32662. doi: 10.1371/journal.pone.0032662

Wang, Y., Yuan, Y., Li, H., Cho, J. H., Huang, D., Gray, L., et al. (2013). The spectrum of circulating RNA, a window into systems toxi-

ology. Toxicol. Sci. 132, 478–482. doi: 10.1093/toxsci/kft014

Wang, K., Zhang, S., Marrzolf, B., Tiroud, P., Bignonnet, A., Hu, Z., et al. (2009). Circulating micro-

RNAs, potential biomarkers for drug-

induced liver injury. Proc. Natl. Acad. Sci. U.S.A. 106, 4402–4407. doi: 10.1073/pnas.0813371106

Walker, M., Z. Yan, Z. Ran, Y., and Pu, J. (2013). Circu-

lating microRNAs are promising novel biomarkers of acute myocardial infarction. In Vivo 27, 1789–1795. doi: 10.2187/inivo.5128

Wells, J. A., Baxter, D. H., Zhang, S., Huang, D. H., Huang, K. H., Lee, M. J., et al. (2010). The microRNA spectrum in 52 body flu-

ids. Clin. Chem. 56, 1735–1741. doi: 10.1373/clinchem.2010.147845

Wolfgang, E. J., Pers, M. F., Poss, C. D., and Zuckerman, K. S. (2007). Gap junction-mediated transport of dsRNA between human embryos

figne-04-00115” — 2013/6/15 — 15:49 — page 7 — #7

www.frontierie.org

June 2013 | Volume 4 | Article 115 | 7

Circulating RNA
stem cells. Biochem. Biophys. Res. Commun. 365, 610–615. doi: 10.1016/j.bbrc.2007.09.055
Wei, L., Zhou, H., Lin, H., Qi, J., Zhu, C., Guo, Z., et al. (2012). Circulating microRNAs are elevated in plasma from severe preeclamptic pregnancy. Reproduction 143, 389–397. doi: 10.1530/REP-11-0504
Xiong, M., Chen, J., Xu, F., Yu, B., Liu, L., Liu, Y., et al. (2011). Microvesicles secreted by macrophages shorten invasion-potentiating microRNA into breast cancer cells. Mol. Cancer 10, 117. doi: 10.1007/4196-10-117
Yao, Q., Xu, H., Zhang, Q. Q., Zhou, H., and Qu, L. H. (2009). MicroRNA-21 promotes cell proliferation and down-regulates the expression of programmed cell death 4 (PDCD4) in HeLa cervical carcinoma cells. Biochem. Biophys. Res. Commun. 388, 539–542. doi: 10.1016/j.bbrc.2009.08.044
Zhao, Z., Zhao, Q., Worick, J., Lockwood, C. M., Woodworth, A., Miskel, K. H., et al. (2012). Circulating microRNA miR-523-3p as a biomarker of ectopic pregnancy. Clin. Chem. 58, 896–905. doi: 10.1373/clinchem.2011.179283
Zhong, X. Y ., Holzgreve, W ., and Huang, D. J. (2008). Isolation of cell-free RNA from maternal plasma. Methods Mol. Biol. 444, 269–275. doi: 10.1007/978-1-59745-066-9_21

Conflict of Interest Statement: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.